One challenge for development of non toxic micro-CT contrast agents is to load a high concentration of an X-ray attenuating element in a nanoparticulate formulation with particle size distribution small enough to avoid accumulation in lungs but large enough to avoid kidney filtration. Binitio Biomedical’s Exia 160 and Exia 160XL meet these requirements with sufficient stealth properties for vascular imaging. In addition, they are made of components which are metabolized by catabolic pathways in the body thus enabling metabolic imaging of the myocardium and brown adipose tissue.
MediLumine is honored to be named a finalist for the 2025 World Molecular Imaging Congress (WMIC) Commercial Innovation of the Year Award. The nomination recognizes
Vascular structure of the tumour. Three-dimensional rendering of the vascular structure of the LM8 osteosarcoma tumour as visualized in μCT after staining with Vascupaint. Background:
